ClinVar Miner

Submissions for variant NM_000363.5(TNNI3):c.434G>A (p.Arg145Gln) (rs397516349)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Laboratory for Molecular Medicine, Partners HealthCare Personalized Medicine RCV000200141 SCV000059947 likely pathogenic Hypertrophic cardiomyopathy 2017-09-08 criteria provided, single submitter clinical testing The p.Arg145Gln variant in TNNI3 has been reported in 10 individuals with HCM an d 1 individual with RCM who also carried a second variant in TNNI3 (Berge 2014, Mogensen 2004, Kimura 1997, van den Wijngaard 2011, Wang 2014, Zou 2013, LMM dat a). This variant has also been reported in ClinVar (Variation ID 43384) and in 2 /17246 East Asian and 2/33578 Latino chromosomes by the Genome Aggregation Datab ase (gnomAD,; dbSNP rs397516349). This variant was predicted to be pathogenic using a computational tool clinically validated b y our laboratory. This tool's pathogenic prediction is estimated to be correct 9 4% of the time (Jordan 2011). In vitro functional studies provide some evidence that the p.Arg145Gln variant may impact protein function (Takahashi-Yanaga 2001) . However, these types of assays may not accurately represent biological functio n. In addition, 2 other pathogenic variants have been reported at this amino aci d position (p.Arg145Gly and p.Arg145Trp), suggesting that this residue has funct ional importance. In summary, although additional studies are required to fully establish its clinical significance, the p.Arg145Gln variant is likely pathogeni c.
GeneDx RCV000159223 SCV000209169 pathogenic not provided 2018-05-18 criteria provided, single submitter clinical testing The R145Q pathogenic variant in the TNNI3 gene has been reported in multiple individuals with HCM (Kimura et al., 1997; Takahashi-Yanaga et al., 2001; Mogensen et al., 2004; Zou et al., 2013; Berge et al., 2014; Wang et al., 2014; Walsh et al., 2017; Weissler-Snir et al., 2017). R145Q was also identified in a mosaic individual with RCM who also harbored a second missense variant in the TNNI3 gene (van den Wijngaard et al., 2011). This variant has also been identified in other unrelated individuals referred for HCM genetic testing at GeneDx, and was found to segregate with disease in three affected relatives from one family. In addition, R145Q is not observed at a significant frequency in large population cohorts (Lek et al., 2016). The R145Q variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. Functional studies demonstrated that the R145Q variant results in a large increase in the Ca2+ sensitivity of cardiac muscle contraction (Takahashi-Yanaga et al., 2001). Furthermore, other pathogenic missense variants at the same residue (R145G, R145W) have been reported in association with cardiomyopathy (Choi et al., 2010; van den Wijngaard et al., 2011), further supporting the functional importance of this residue.
Invitae RCV000200141 SCV000253695 pathogenic Hypertrophic cardiomyopathy 2020-10-27 criteria provided, single submitter clinical testing This sequence change replaces arginine with glutamine at codon 145 of the TNNI3 protein (p.Arg145Gln). The arginine residue is moderately conserved and there is a small physicochemical difference between arginine and glutamine. This variant is present in population databases (rs397516349, ExAC 0.01%). This variant has been reported in multiple unrelated individuals with hypertrophic cardiomyopathy (HCM) (PMID: 9241277, 15607392, 23283745, 24111713, 25132132). ClinVar contains an entry for this variant (Variation ID: 43384). Experimental studies have shown that this missense change increases the calcium sensitivity of cardiac muscle contraction in vitro (PMID: 11735257). Two different amino acid changes at this position (Arg145Trp and Arg145Gly) have been reported as pathogenic sequence changes (PMID: 11735257, 20641121, 23610579), indicating that this amino acid position is important for TNNI3 protein function. For these reasons, this variant has been classified as Pathogenic.
Blueprint Genetics RCV000208273 SCV000264250 pathogenic Primary familial hypertrophic cardiomyopathy 2015-12-01 criteria provided, single submitter clinical testing
Center for Human Genetics,University of Leuven RCV000200141 SCV000579525 likely pathogenic Hypertrophic cardiomyopathy 2017-02-09 criteria provided, single submitter clinical testing ACMG score likely pathogenic
Ambry Genetics RCV000621089 SCV000740143 likely pathogenic Cardiovascular phenotype 2019-09-20 criteria provided, single submitter clinical testing The p.R145Q variant (also known as c.434G>A), located in coding exon 7 of the TNNI3 gene, results from a G to A substitution at nucleotide position 434. The arginine at codon 145 is replaced by glutamine, an amino acid with highly similar properties. This alteration has been reported in individuals with hypertrophic cardiomyopathy (HCM) and restrictive cardiomyopathy (RCM); however, in some cases, it co-occurred with alterations in TNNI3 or other cardiac-related genes (Kimura A et al. Nat Genet. 1997;16:379-82; Mogensen J et al. J Am Coll Cardiol. 2004;44:2315-25; van den Wijngaard A et al. Neth Heart J. 2011;19:344-51; Zou Y et al. Mol Biol Rep. 2013;40:3969-76; Berge KE et al. Clin Genet. 2014;86:355-60; Wang J et al. Eur J Heart Fail. 2014;16:950-7). In vitro functional studies indicate this alteration results in reduced intrinsic inhibitory activity, increased calcium sensitivity of myofibrillar ATPase activity and increased force generation of skinned muscle fibers (Takahashi-Yanaga F et al. J Mol Cell Cardiol. 2001;33:2095-107). In addition, other alterations affecting this amino acid (p.R145G, c.433C>G and p.R145W, c.433C>T) have also been reported in association with cardiomyopathy (Kimura A et al. Nat Genet. 1997;16:379-82; van den Wijngaard A et al. Neth Heart J. 2011;19:344-51). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the majority of available evidence to date, this variant is likely to be pathogenic.
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease,Montreal Heart Institute RCV000159223 SCV000748022 pathogenic not provided 2017-04-19 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000763057 SCV000893542 pathogenic Dilated cardiomyopathy 2A; Familial restrictive cardiomyopathy 1; Dilated cardiomyopathy 1FF; Familial hypertrophic cardiomyopathy 7 2018-10-31 criteria provided, single submitter clinical testing
Agnes Ginges Centre for Molecular Cardiology,Centenary Institute RCV000200141 SCV001245078 likely pathogenic Hypertrophic cardiomyopathy 2018-09-05 criteria provided, single submitter research This variant has been identified as part of our research program. Refer to the 'condition' field for the phenotype of the proband(s) identified with this variant. For further information please feel free to contact us.
Color Health, Inc RCV001178632 SCV001343131 likely pathogenic Cardiomyopathy 2020-03-26 criteria provided, single submitter clinical testing
CeGaT Praxis fuer Humangenetik Tuebingen RCV000159223 SCV001746338 pathogenic not provided 2021-04-01 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.